PURPOSE: The purpose of this study was to enhance adherence among older (aged 55 years and older) African American men enrolled in a cancer screening trial for prostate, lung, and colorectal cancer. For this study, we defined adherence as completing the trial screenings. DESIGN AND METHODS: We used a randomized trial design. Case managers contacted intervention group participants (n=352) at least monthly by telephone and provided information and referral services. The control group included 351 participants. RESULTS: Among participants with low income, those in the intervention group had higher screening adherence rates than did participants in the control group for (a) prostate-specific antigen test for prostate cancer (74.3% vs 53.0%, p=.001), (b) digital rectal exam for prostate cancer (66.2% vs 46.1%, p=.011), and (c) chest x-ray for lung cancer (70.9% vs 51.3%, p=.012). We found no statistically significant differences in adherence rates for flexible sigmoidoscopy screening for colorectal cancer. In contrast, among participants with moderate-to-high income, we found no statistically significant differences in adherence rates between intervention and control group participants for any of the screening tests. IMPLICATIONS: The case management intervention was effective in enhancing adherence among participants with the lowest income, who in many studies are the most difficult to retain.
RCT Entities:
PURPOSE: The purpose of this study was to enhance adherence among older (aged 55 years and older) African American men enrolled in a cancer screening trial for prostate, lung, and colorectal cancer. For this study, we defined adherence as completing the trial screenings. DESIGN AND METHODS: We used a randomized trial design. Case managers contacted intervention group participants (n=352) at least monthly by telephone and provided information and referral services. The control group included 351 participants. RESULTS: Among participants with low income, those in the intervention group had higher screening adherence rates than did participants in the control group for (a) prostate-specific antigen test for prostate cancer (74.3% vs 53.0%, p=.001), (b) digital rectal exam for prostate cancer (66.2% vs 46.1%, p=.011), and (c) chest x-ray for lung cancer (70.9% vs 51.3%, p=.012). We found no statistically significant differences in adherence rates for flexible sigmoidoscopy screening for colorectal cancer. In contrast, among participants with moderate-to-high income, we found no statistically significant differences in adherence rates between intervention and control group participants for any of the screening tests. IMPLICATIONS: The case management intervention was effective in enhancing adherence among participants with the lowest income, who in many studies are the most difficult to retain.
Authors: An-Wen Chan; Jennifer M Tetzlaff; Peter C Gøtzsche; Douglas G Altman; Howard Mann; Jesse A Berlin; Kay Dickersin; Asbjørn Hróbjartsson; Kenneth F Schulz; Wendy R Parulekar; Karmela Krleza-Jeric; Andreas Laupacis; David Moher Journal: BMJ Date: 2013-01-08
Authors: Stephen S Grubbs; Blase N Polite; John Carney; William Bowser; Jill Rogers; Nora Katurakes; Paula Hess; Electra D Paskett Journal: J Clin Oncol Date: 2013-04-15 Impact factor: 44.544
Authors: Michael K Dougherty; Alison T Brenner; Seth D Crockett; Shivani Gupta; Stephanie B Wheeler; Manny Coker-Schwimmer; Laura Cubillos; Teri Malo; Daniel S Reuland Journal: JAMA Intern Med Date: 2018-12-01 Impact factor: 21.873
Authors: Karen A Robinson; Victor D Dinglas; Vineeth Sukrithan; Ramakrishna Yalamanchilli; Pedro A Mendez-Tellez; Cheryl Dennison-Himmelfarb; Dale M Needham Journal: J Clin Epidemiol Date: 2015-06-10 Impact factor: 6.437
Authors: Marvella E Ford; Laura A Siminoff; Elisabeth Pickelsimer; Arch G Mainous; Daniel W Smith; Vanessa A Diaz; Lea H Soderstrom; Melanie S Jefferson; Barbara C Tilley Journal: Health Soc Work Date: 2013-02
Authors: Kathryn B Arnold; John A Hermos; Karen B Anderson; Lori Minasian; Catherine M Tangen; Jeffrey F Probstfield; Elise D Cook Journal: Cancer Epidemiol Biomarkers Prev Date: 2014-09-21 Impact factor: 4.254